Chardan is pleased to act as Exclusive Financial Advisor to VBL Therapeutics in their announced definitive merger agreement with Noteable Labs.

The merger will create a Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”).

To read more about the transaction, click here.